AstraZeneca PLCAZN:LSE

3,928
31.50 / 0.80 %
3.24m
11.88 %
0.6247
Close in GBXToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Apr 29 2016 17:54 BST.

Income statement in USD

Year on year AstraZeneca PLC grew net income 129.12% from 1.23bn to 2.83bn despite declining revenues. View full income statement

REVENUE
Gross margin81.84%
Net profit margin11.44%
Operating margin16.65%
NET INCOME
Return on assets4.76%
Return on equity14.82%
Return on investment6.54%

Growth rates in USD

Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items increased 128.94%. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked below the industry average relative to its peers.

DIVIDEND PER SHARE
Div yield(5 year avg)0.09%
Div growth rate (5 year)1.89%
Payout ratio (TTM)85.03%
EARNINGS PER SHARE
EPS growth(5 years)-16.7033
EPS (TTM) vs
TTM 1 year ago
127.86

Cash flow in USD

In 2015, AstraZeneca PLC did not generate a significant amount of cash. However, the company earned 3.32bn from its operations for a Cash Flow Margin of 13.45%. In addition the company generated 878.00m cash from financing while 4.24bn was spent on investing. View full cash flow statement

CASH FLOW
Cash flow per share2.98
Price/Cash flow per share13.19
CASH
Book value per share10.01
Tangible book value per share-8.6757

Balance sheet in USD

AstraZeneca PLC has a Debt to Total Capital ratio of 44.85%, a higher figure than the previous year's 42.78%. View full balance sheet

TOTAL ASSETS
Current ratio1.08
Quick ratio0.9324
TOTAL DEBT
Total debt/total equity0.8141
Total debt/total capital0.4485
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.